Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ACE2016

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Acepodia

Drug class:

EGFR inhibitor, γδ TCR modulator

Related drugs:

‹

autologous γδ T lymphocytes (0)

ALEXIS-ISO-1 (0)

NK/γδ T cell-enriched cell therapy (0)

anti-CD19-CAR γδT (0)

γδT Cell infusion (0)

γδT Cell infusion agent (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

BTN2A1/3A1-Fc-CD19scFv (0)

CD7-UCAR-γδT cells (0)

ET1402L1-ARTEMIS T cells (0)

Gamma delta T-cells (0)

autologous γδ T lymphocytes (0)

ALEXIS-ISO-1 (0)

NK/γδ T cell-enriched cell therapy (0)

anti-CD19-CAR γδT (0)

γδT Cell infusion (0)

γδT Cell infusion agent (0)

›

EGFR expression	Solid Tumor	EGFR expression	Solid Tumor	ACE2016 Sensitive: D – Preclinical ACE2016 Sensitive : D	ACE2016 Sensitive: D – Preclinical ACE2016 Sensitive : D
EGFR expression	Breast Cancer	EGFR expression	Breast Cancer	ACE2016 Sensitive: D – Preclinical ACE2016 Sensitive : D	ACE2016 Sensitive: D – Preclinical ACE2016 Sensitive : D